Updates are available Correction dated 2024-08-27
Click to view Correction: https://doi.org/10.1007/s10147-024-02596-y
-
Authors
Inayama, Yoshihide
Mizuno, Kayoko
Yamaguchi, Ken
Hamanishi, Junzo
Takeuchi, Masato
Egawa, Miho
Mandai, Masaki
Kawakami, Koji https://orcid.org/0000-0002-7477-4071
- License Information
-
More Information
Article History
Received: 5 September 2022
Accepted: 27 December 2022
First Online: 4 January 2023
Change Date: 27 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10147-024-02596-y
Declarations
:
: M. T. received consultation fees from Eisai Co., Ltd.; K. K. received research funds from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Mitsubishi Corporation, and Real World Data Co., Ltd.; consulting fees from LEBER Inc., JMDC Inc., Shin Nippon Biomedical Laboratories Ltd., and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems, Inc.; honorarium from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, Pharma Business Academy, and Toppan Inc.
: This study was approved by the Kyoto University Graduate School and Faculty of Medicine Ethics Committee (reference number: R3451). The need to obtain written informed consent from patients was waived, because the data were anonymized.
